To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
CURE Communications Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Hodgkin lymphoma survivors may be more likely to develop subsequent estrogen receptor (ER)-negative or -positive breast cancer compared to the general population.
Katie Kosko
Rick Boulay, a gynecologic oncologist and classically trained singer, will host a performance to raise money for cancer charities.
New drugs bring advancements to acute myeloid leukemia after 40 years.


Khevin Barnes
Just surviving can be an up-and-down experience.
Barbara Tako
Do not stop after you create your medical team. Create a support team for yourself, too.
Bonnie Annis
When the doctor-patient relationship is compromised, it's sometimes necessary for a change.

CURE Connections®

Heather Ambrose, Martha Raymond, and Tim Wert recognize unmet needs in the management of patients diagnosed with GI cancers.
Heather Ambrose, Martha Raymond, and Tim Wert highlight the pharmaceutical industry’s investment in conducting research and clinical trials to improve the care of patients impacted by GI cancers.
Experts Heather Ambrose and Tim Wert define the pharmaceutical industry’s role in the GI cancer space and discuss strategies to address educational barriers between patients and physicians.


William G. Wierda, M.D., Ph.D.
William G. Wierda, M.D., Ph.D., medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses how to best combine and sequence therapies for patients with chronic lymphocytic leukemia (CLL).
Joshua Richter, M.D.
A new patient-reported outcomes tool is helping to shift the way end-of-life and depression-related conversations are occurring between patients with multiple myeloma and their health care teams.
Michael J. Overman, M.D.
Genetic testing – particularly for microsatellite instability (MSI) – is an important step for all patients diagnosed with colorectal cancer.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment


Healthcare Professional

Not Applicable